ANNEE 2016

Publié le 30/03/2018 à 15h56

Alberto C, Konstantinou MP, Martinage C, Casassa E, Tournier E, Bagheri H, Sibaud V, Mourey L, Mazereeuw-Hautier J, Meyer N, Paul C, Bulai Livideanu C. Enzalutamide induced acute generalized exanthematous pustulosis. J Dermatol Case Rep. 2016 ;10 : 35-38.

Bagheri H, Laroche ML, Montastruc JL. Les nouveaux défis de la pharmacovigilance. Therapie. 2 016 ;71:119-20.

Bagheri H, Laroche ML, Montastruc JL. Pharmacovigilance : The new challenges. Therapie. 2016 ;71:121-22.

Bagheri H, Lacroix I, Guitton-Bondon E, Damase-Michel C, Montastruc JL. Cyberpharmacovigilance : What is the usefulness of the social networks in pharmacovigilance ?. Therapie. 2016 ;71:235-39.

Bagheri H, Lacroix I, Guitton-Bondon E, Damase-Michel C, Montastruc JL. Cyberpharmacovigilance : les réseaux sociaux sont-ils utiles en pharmacovigilance ?. Therapie. 2016 ;71:229-33.

Beau AB, Montastruc JL, Lacroix I, Montastruc F, Hurault-Delarue C, Damase-Michel C. Atropinic burden of drugs during pregnancy and psychological development of children : a cohort study in the EFEMERIS database. Br J Clin Pharmacol. 2016 ;82:478-486.

Béné J, Moulis G, Bennani I, Auffret M, Coupe P, Babai S, Hillaire-Buys D, Micallef J, Gautier S ; French Association of Regional PharmacoVigilance Centres. Bullous pemphigoid and dipeptidyl peptidase IV-inhibitors : A Case/Non-Case study in the French Pharmacovigilance Database. Br J Dermatol. 2016 ;175:296-301.

Bondon-Guitton E, Combret S, Pérault-Pochat MC, Stève-Dumont M, Bagheri H, Huguet F, Despas F, Pathak A, Montastruc JL. Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy. Target Oncol. 2016 ;11:549-552.

Bondon-Guitton E, Despas F, Becquemont L. The contribution of pharmacogenetics to pharmacovigilance. Therapie. 2016 ;71:223-28.

Bondon-Guitton E, Despas F, Becquemont L. Apport de la Pharmacogénétique à la pharmacovigilance. Therapie. 2016 ;71:217-22.

Bounhoure JP, Bouvenot G, Montastruc JL. Cardiovascular risks and nonsteroidal anti-inflammatory drugs in the elderly recommendations for prescription. Bull. Acad. Natle Méd., 2015 ;199:949-957.

Bourgeois AL, Auriche P, Palmaro A, Montastruc JL, Bagheri H. Risk of hormonotherapy in transgender people : Literature review and data from the French Database of Pharmacovigilance. Ann Endocrinol (Paris). 2016 ;77:14-21.

Bouvenot G, Bounhoure JP, Montastruc JL, Vacheron A. Rapport sur les anticoagulants oraux directs (AOD), (antérieurement appelés « nouveaux anticoagulants oraux » ou NACO). Bull. Acad. Natle Méd..2014 ;198:1157-1195.

De Germay S, Montastruc JL, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Rascol O, Pariente A, Bégaud B, Montastruc F. Atropinic (Anticholinergic) Burden in Parkinson’s Disease. Mov Disord. 2016 ;31:632-6.

Durrieu G, Jacquot J, Mège M, Bondon-Guitton E, Rousseau V, Montastruc F, Montastruc JL. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre : A Descriptive Study. Drug Saf. 2016 ;39:1189-1195.

Faillie JL, Montastruc F, Montastruc JL, Pariente A. L’apport de la pharmaco-épidémiologie à la pharmacovigilance. Therapie. 2016 ;71:203-09.

Faillie JL, Montastruc F, Montastruc JL, Pariente A. Pharmacoepidemiology and its input to pharmacovigilance. Therapie. 2016 ;71:211-16.

Giroud JP, Montastruc JL. Séance thématique : La Pharmacoépidémiologie. Bull Acad Natle Med. 2015 ;199:261-62.

Giroud JP, Montastruc JL. Les médicaments du rhume à base de vasoconstricteurs doivent être prescrits sur ordonnance. Bull. Acad. Natle Méd..2015 ;199:947-48.

Guinard E, Bulai Livideanu C, Barthelemy H, Viguier M, Reguiai Z, Richard MA, Jullien D, Beneton N, Bara C, Vabres P, Grandvuillemin A, Marguery MC, Amelot F, Konstantinou MP, Bagheri H, Paul C ; for the French Psoriasis Research Group. Active tuberculosis in psoriasis patients treated with TNF antagonists : a French nationwide retrospective study. JEADV. 2016 ;30:1336-41.

Hallberg P, Eriksson N, Ibañez L, Bondon-Guitton E, Kreutz R, Carvajal A, M Isabel Lucena M, Sancho Ponce E, Molokhia M, Martin J, Axelsson T, Yue QY, K E Magnusson P, Wadelius M, for the EuDAC collaborators*. Genetic variants associated with antithyroid drug-induced agranulocytosis : a genome-wide association study in a European population. Lancet Diabetes Endocrinol. 2016 ;4:507-16.

Hauviller L, Eyvrard F, Garnault V, Rousseau V, Molinier L, Montastruc JL, Bagheri H. Hospital re-admission associated with adverse drug reactions in patients over the age of 65 years. Eur J Clin Pharmacol. 2016 ;72:631-9.

Hurault-Delarue C, Chouquet C, Savy N, Lacroix I, Beau AB, Montastruc JL, Damase-Michel C. How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women ? Pharmacoepidemiol Drug Saf. 2016 ;25:770-77.

Hurault-Delarue C, Damase-Michel C, Finotto L, Guitard C, Vayssière C, Montastruc JL, Montastruc F, Lacroix I. Psychomotor developmental effects of prenatal exposure to psychotropic drugs : a study in EFEMERIS database. Fund Clin Pharmacol. 2016 ;30:476-482.

Lacroix I, Beau AB, Hurault-Delarue C, Bouilhac C, Petiot D, Vayssière C, Vidal S, Montastruc JL, Damase-Michel C. First epidemiological data for venotonics in pregnancy from the EFEMERIS database. Phlebology. 2016 ;31:344-8.

Mauran A, Goze T, Abadie D, Bondon-Guitton E, Chevrel P, Schmitt L, Montastruc JL, Montastruc F. Mania associated to Ranitidine : a case report and review of literature. Fundam Clin Pharmacol. 2016 ;30:294-6.

Montastruc F, Salvo F, Arnaud M, Bégaud B, Pariente A. Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias : A Disproportionality Analysis Using Data from Vigibase®. Drug Saf. 2016 ;39:689-96.

Montastruc F, Montastruc G, Montastruc JL, Revet A. Cardiovascular safety of methylphenidate should also be considered in adults !. Bmj. 2016 ;353:i3418.

Montastruc JL, Chebane L, Bagheri H. Drug-Induced Hyperglycaemia and Diabetes. Drug Saf. 2016 ;39:465-66.

Montastruc JL, Emmanuelle Bondon-Guitton E, Abadie D, Lacroix I, Berrenia A, Pugnet G, Durrieu G, Sailler L, Giroudb JP, Damase-Michel M, Montastruc F. Pharmacovigilance : Risques et effets indésirables de l’automédication. Therapie. 2016 ;71:249-255.

Montastruc JL, Emmanuelle Bondon-Guitton E, Abadie D, Lacroix I, Berrenia A, Pugnet G, Durrieu G, Sailler L, Giroudb JP, Damase-Michel M, Montastruc F. Pharmacovigilance, risks and adverse effects of self-medication. Therapie. 2016 ;71:257-262.

Montastruc JL, Sommet A, Montastruc F, Moulis G, Bagheri H, Damase-Michel M, Lapeyre-Mestre M.  Qu’est-ce que la pharmacoépidémiologie. Pharmacoepidemiology : definition, methods and applications. Bull Acad Natle Med. 2015 ;199:263-73.

Olivier-Abbal P. Mesure de l’évitabilité des effets indésirables médicamenteux en France : état des lieux en 2015. Therapie. 2016 ;71:187-194.

Olivier-Abbal P. Measuring the preventability of adverse drug reactions in France : A 2015 overview. Therapie. 2016 ;71:195-202.

Olivier-Abbal P, Gimbert A, Colin AL, Salvo F, Becker M, Marty V, Montastruc JL, Petitpain N. Serious adverse drug events related to non-investigational drugs in academic clinical trials : another source of safety data for risk assessment ? Br J Clin Pharmacol. 2016 ;82:1069-75.

Palosse-Cantaloube L, Hurault-Delarue C, Beau AB, Montastruc JL, Lacroix I, Damase-Michel C. Risk of infections during the first year of life after in utero exposure to drugs acting on immunity : a population-based cohort study. Pharmacol Res. 2016 ;113:557-52.

Pugnet G, Sailler L, Fournier JP, Bourrel R, Montastruc JL, Lapeyre-Mestre M.  Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis : Effect of Statin Exposure. A French Population-based Study. J Rheumatol. 2016 ;43:2162-2170.

Récoché I, Rousseau V, Bourrel R, Lapeyre-Mestre M, Chebane L, Despas F, Montastruc JL, Bondon-Guitton E. Drug-drug interactions with imatinib : An observational study. Medicine (Baltimore). 2016 ;95:e5076.

Saliba L, Moulis G, Abou Taam M, Rousseau V, Chebane L, Petitpain N, Baldin B, Pugnet G, Montastruc JL, Bagheri H. Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone : a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. Fundam Clin Pharmacol. 2016 ;30:162-71.

Thorel J, McCambridge C, Piau A, Secher M, Magre É, Montastruc JL, Bagheri H. Proton pump inhibitors : Real indication or trivialized prescription ?. Therapie. 2016 ;71:589-93.

Tournaire G, Despas F, Huguet F, Montastruc JL, Bondon-Guitton E. Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib : a case report. J Clin Pharm Ther. 2016 ;41:360-61.

Tranchard F, Hein C, Lacombe J, Villars H, Montastruc JL, Despas F. Medication errors and look-alike tablets : the splitting issue. Pharmacoepidemiol Drug Saf. 2016 ;25:1002-3.

Villeneuve C, Laroche ML, Essig M, Merville P, Kamar N, Coubret A, Lacroix I, Bouchet S, Fruit D, Marquet P, Rousseau A ; EPIGREN study group. Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation. Transplantation. 2016 ;100:640-7.